Evolution Gaming’s Stock Tanks After Q3 Miss and Rival Smear Allegations
23 October 2025
5 mins read

Evolution Gaming’s Stock Tanks After Q3 Miss and Rival Smear Allegations

EVO.ST ~SEK 668.3 (Oct 23, 2025); ∼–8% over the week marketscreener.com tradingview.com. YTD ↓∼30% tradingview.com. Market cap ~SEK 15.5 bn marketscreener.com. Q3 2025 revenue €507.1 M (–2.4% YoY; consensus €536 M) marketscreener.com. Adjusted EBITDA €337 M (66.5% margin) vs forecast €356 M marketscreener.com. EPS €1.25 (below €1.57 est.) marketscreener.com. Dividend yield ~4.2% (DPS 30.64 SEK) investing.com. Analyst consensus: mostly “Buy” with ~SEK 938 average target tipranks.com stocksguide.com (range SEK 656–1,512 stocksguide.com). Evolution holds ~45% of the global live-casino market (vs ~30% for Playtech, 25% Pragmatic) pokertube.com pokertube.com, and has 20+ studios worldwide marketscreener.com. Major developments: October launch of Ezugi games in US agbrief.com; Jan 2025 Hasbro partnership to create Monopoly-branded casino games evolution.com; Brazilian studio opened July 2025 yogonet.com. Recent news: Fallout from a 2021 “smear report” has intensified, with Evolution accusing rival Playtech of commissioning it sbcnews.co.uk, sparking a steep selloff in Playtech’s stock 1 .

Stock Performance & Trading Update

Evolution AB (EVO.ST) shares are under pressure. As of Oct 23, 2025 the stock traded around SEK 668, down about 8% over the prior week marketscreener.com tradingview.com. Over the past month EVO has fallen ~20% tradingview.com. Trading sites note the stock is down roughly 9.5% week-on-week and nearly 30% year-to-date tradingview.com. This decline accelerated on Oct 21–22 after Q3 results disappointed and media reports blew up a long-running rivalry.

Q3 2025 Results – Miss and Management Comments

On Oct 23 Evolution reported Q3 2025 net revenues of €507.1 million, a 2.4% decline from last year and below the €536 M consensus marketscreener.com. Adjusted EBITDA came in at €337 M (66.5% margin) versus an expected €356 M marketscreener.com. Net profit fell to €252.3 M (EPS €1.25 vs €1.57 expected) marketscreener.com. CEO Martin Carlesund acknowledged that “we are not satisfied with our growth so far this year,” citing uneven performance marketscreener.com. He noted Europe, North America and Latin America were “fair to good,” but Asia remains “far from satisfactory” due to persistent cybercrime and regulatory uncertainty marketscreener.com marketscreener.com. Evolution raised counter-fraud measures in Asia, but Carlesund warned some measures “impacted legitimate end users,” curbing revenue marketscreener.com. Notably, a volatile new regulatory regime in the Philippines and nascent regulation in India also weighed on Asian growth marketscreener.com. Despite the top-line miss, Carlesund said disciplined cost control helped lift margins “within our full-year forecast of 66–68%” marketscreener.com, and reiterated that the company expects to remain in that range through Q4 2 .

Rival Smear Campaign Drama

Just before the earnings release, Evolution made headlines by unmasking a rival in a smear-campaign scandal. On Oct 21 the company publicly identified London-listed Playtech as the client behind a 2021 private intelligence report (by Black Cube) that alleged Evolution had illicit operations in China, Iran and other markets. Evolution said court documents show Playtech paid Black Cube about £1.8 million to produce and leak the report, “to damage our business and reputation” sbcnews.co.uk. The revelation triggered a severe market reaction: Playtech’s stock plunged roughly 25–30% in one day, wiping out ~£300 million of value sbcnews.co.uk reuters.com. Playtech quickly denied any “smear campaign,” defending its probe as a legitimate investigation sbcnews.co.uk reuters.com. The two companies have now traded legal volleys, with Evolution vowing to “hold Playtech … responsible” for the defamation sbcnews.co.uk. This public feud has spotlighted Evolution’s industry fight but also briefly boosted its own stock (up ~1% on Oct 21 even as Playtech sank) 3 .

Industry Position & Global Expansion

Evolution remains the dominant live-casino game provider worldwide. It reported €2.21 billion in revenue in 2024, of which ~80% was live casino (roulette, blackjack, baccarat, etc.) pokertube.com. As of mid-2025 the firm was estimated to have about 45% of the global live-casino market – far ahead of closest rivals (Playtech ~30%, Pragmatic Play ~25%) pokertube.com pokertube.com. Evolution runs over 1,700 live tables globally and works with 800+ gaming operators pokertube.com tipranks.com. It has built a broad international footprint: at end-2023 Evolution had 20 live-studio production facilities spanning the US (5 studios), Canada, Europe (Malta, Spain, Baltic States, etc.) and Latin America marketscreener.com. In early 2025 Evolution pressed these advantages: it opened a live studio in São Paulo, Brazil in July (the first supplier licensed on day one of Brazil’s new gaming law) yogonet.com, and built Portuguese-speaking Blackjack tables to appeal to Brazilians yogonet.com. In North America, Evolution has five U.S. studios and in Oct 2025 launched its acquired brand Ezugi in New Jersey agbrief.com (streaming from a new Atlantic City studio). CEO Jacob Claesson said the Ezugi rollout “is an important step in our North American growth strategy” agbrief.com; a Michigan studio is slated for early 2026 agbrief.com. Evolution’s product innovation remains strong – it recently rolled out new live games (e.g. Lightning Bac Bo, First Person Baccarat) and is developing many more titles (over 100 planned in 2025 pokertube.com evolution.com). In Jan 2025 it announced an exclusive deal with Hasbro to build casino games using the Monopoly brand and other Hasbro IP; new Monopoly-themed live game shows and slots will debut in 2026 evolution.com evolution.com. These global moves underscore Evolution’s strategy of localized content and premium branding.

Analyst Views & Forecasts

Analysts are conflicted. TipRanks notes the “most recent analyst rating” on EVO is a Buy with a SEK1,000 price target tipranks.com. Aggregators show about half of analysts still bullish: one consensus tracker cites an average 2025 target near kr938, implying ~30% upside stocksguide.com. TradingView data similarly lists a high target ~1,342 SEK and a low ~598 SEK tradingview.com. By contrast, some research houses have trimmed forecasts after recent news: Cantor Fitzgerald on Oct 21 cut Evolution’s rating to Underweight and its 12‑month target to SEK 635 marketscreener.com; JP Morgan likewise reduced its target to SEK 675 marketscreener.com. These downgrades cite lower growth visibility amid Asian headwinds and competitive pressure. On the other hand, analysts who remain constructive often highlight Evolution’s resilient margins and long-term opportunities in regulated markets. In its Q3 presentation, Evolution reconfirmed FY EBITDA margin guidance (66–68%), and executives reiterated confidence that cost control and a diversified revenue base will sustain profitability.

Risks & Opportunities

Evolution’s chief risks include its heavy exposure to Asia, where cyber-attacks and regulatory crackdowns have repeatedly dented results marketscreener.com. The company warned that fighting fraud is a “constant balancing act” that can sometimes depress Asian revenue marketscreener.com. Regulatory scrutiny is rising: in 2025 the UK Gambling Commission even reviewed Evolution’s license after finding some of its games on unlicensed sites pokertube.com. Competition is fierce; besides Playtech and Pragmatic, newer entrants like Playtech’s B2B spinoffs and smaller studios are nipping at Evolution’s heels. The recent defamation saga also poses a reputational risk, depending on legal outcomes. However, the company’s large scale, premium brand and high recurring revenue from longtime operator contracts are strong moats. Opportunities are plentiful: legalized gaming in the U.S. and Latin America, plus new B2B products (AI-driven game design, RNG slots) could fuel growth. The Hasbro deal and U.S. expansion (Ezugi’s US launch, planned Michigan studio) open substantial new revenue streams.

In summary, Evolution remains widely viewed as the world leader in live casino, with robust free cash flow and dividends (yield ~4.2% investing.com). The recent Q3 miss and headlines drove short-term weakness, but many analysts still see upside if management navigates Asia’s challenges and captures growth in North America and LatAm marketscreener.com pokertube.com. As one strategist noted, “Evolution continues to set the standard” in this industry pokertube.com. Investors will watch upcoming quarters closely to see if the company can translate its market share and product pipeline into renewed growth.

Sources: Company filings and press releases marketscreener.com evolution.com agbrief.com yogonet.com; financial news and analysis (Reuters, Marketscreener/Finwire) marketscreener.com sbcnews.co.uk reuters.com; industry interviews and reports pokertube.com tipranks.com; stock data aggregator tradingview.com stocksguide.com; Investing.com 4 .

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
New York, Feb 7, 2026, 09:35 EST — Market closed. Roivant Sciences Ltd shares leapt on Friday after the company reported positive mid-stage results for its immune-modulating drug brepocitinib in a rare skin disease, and paired the readout with its quarterly financial update. The Nasdaq-listed stock closed up 22.4% at $25.82, leaving traders to gauge whether the move has legs when U.S. markets reopen on Monday, Feb. 9. It matters because Roivant is trying to turn a late-stage pipeline into approvals, and the market has been quick to reward biotechs that can show clean efficacy in controlled trials. The company
Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
iPhone 17 Air vs Samsung Galaxy Z Flip 6 vs Google Pixel Fold 2: Apple’s Slim Marvel Faces Foldable Rivals
Previous Story

Apple Slashes iPhone Air Production Amid Disappointing Sales – What’s Next for AAPL?

Crypto Crash or Comeback? Yueda Digital (YDKG) Stock Crashes 90% After Fundraise, Then Bounces – What’s Next
Next Story

Crypto Crash or Comeback? Yueda Digital (YDKG) Stock Crashes 90% After Fundraise, Then Bounces – What’s Next

Go toTop